QSQiyang Shen

Qiyang Shen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Qiyang Shen has a total of 24 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Unmasking Hidden High-Risk Neuroblastoma: ML-Driven CMBs Refine Conventional Risk Stratification –Two case reports

    by Pan Sirui, Wang Xu, Jianfeng Zhou, Qiyang Shen, Nan Xie, Li Tao

    Background Neuroblastoma (NB) is the most frequent solid cancer of early childhood. Owing to the significant heterogeneity of NB, which results in variation in treatment response and outcomes, the International Neuroblastoma Risk Group (INRG) and Children’s Oncology Group (COG) staging systems have been specifically developed to facilitate accurate risk stratification of patients. Our current biological and clinical understanding of neuroblastoma still remains incomplete. Conventional systems may have overlooked some biomarkers that have yet to be discovered. Some low/intermediate-risk cases exhibit aggressive behavior, which highlights the limitations of current risk stratification. Recent studies advocate for the incorporation of Machine Learning(ML) to enhance risk stratification in NB. Case Description Two children (Case 1: male, 9y; Case 2: female, 3y) were classified as low/intermediate-risk by INRG/COG but experienced rapid recurrence and progression. Our previous studies, which focused on Cellular Morphometric Biomarkers (CMBs) in conjunction with large language models (LLM) in NB, reclassified these two cases as high-risk, aligning with their poor outcomes. Conclusion By applying deep learning-based CMBs derived from pathological images and enhanced by LLM, these cases were reclassified as high-risk, thereby highlighting the potential corrective effect of the ML-based stratification model on treatment decisions and confirming its clinical value as an independent prognostic factor.

  • Clinical and Genetic Characteristics of Pediatric Colorectal Cancer

    by Qiyang Shen, Yong Zhou, Xingyu Liu, Jian Li, Sirui Pan, Nan Xie, Xinrong Lin, Li Zhou, Jianfeng Zhou, Tao Li

    Background: Compared to colorectal cancer (CRC) in adults, CRC in children is extremely rare. Although its incidence has increased recently, there is a lack of clinical research on the disease. Inherited cancer susceptibility syndromes (ICSS), a group of disorders in which patients are predisposed to susceptibility to a wide range of tumors as a result of pathogenic mutations in genes in their germ line, are an important cause of CRC in children. Delayed diagnosis due to atypical clinical presentation, as well as limited awareness of ICSS among doctors, contributes to poor outcomes in juvenile CRC patients. Therefore, improving clinicians’ understanding of the diagnosis and treatment of the disease is crucial to enhancing children's prognosis with CRC.Methods: Clinical data and laboratory reports were collected from eight pediatric patients diagnosed with CRC at the Children's Hospital of Nanjing Medical University between 2020 and 2023. The clinical and genetic characteristics of these patients were evaluated and compared with other patients with early‐onset CRC in the literature.Results: A total of 8 children with CRC were enrolled in the study, including 5 male and 3 female children, with a median age of 140 (73–177) months. The main clinical manifestations were unexplained abdominal pain, abdominal distension, vomiting, and hematochezia. Three cases of intestinal obstruction and two cases of intestinal intussusception occurred among the patients. All eight children underwent surgical treatment, including one case of snare resection of rectal polyp, five cases of subtotal colectomy, and two cases of radical resection of CRC. One case of radical resection of CRC utilized laparoscopic and colonoscopic combined resection guided by indocyanine green (ICG) fluorescence navigation system. Postoperative combination of pathological pictures and immunohistochemical (IHC) staining results confirmed high‐grade squamous intraepithelial lesion (HSIL) in Case 1, and mucinous adenocarcinoma in the remaining seven cases. Out of eight pediatric patients with CRC, except for Case 1 and Case 7, who did not undergo chemotherapy, the remaining six patients all received postoperative chemotherapy; among them, the patients in Cases 1, 6, 7, and 8 achieved complete remission, whereas the patients in Cases 2 and 4 died due to postoperative recurrence and distant metastasis, the patient in Case 3 is still undergoing chemotherapy, and the patient in Case 5 was lost to follow‐up after surgery. The results of the genetic test report showed that two children had ICSS caused by mismatch gene repair system defects (deficient MMR, dMMR); in Case 3, the child's genetic test results showed heterozygous mutation of MSH2 in the MMR gene, with high microsatellite instability (MSI‐H), and the results of the methylation test of the MLH1 gene were negative, which, combined with the family history of heterozygous mutation of the MSH2 gene, ruled out sporadic CRC and led to the diagnosis of Lynch syndrome (LS); Case 8 genetic testing showed two heterozygous mutations in the MMR gene PMS2 with microsatellite stabilization (MSS), and a diagnosis of constitutional mismatch repair deficiency (CMMRD) was considered.Conclusion: Pediatric CRC is confronted with delayed diagnosis and poor clinical prognosis, mainly due to nonspecific clinical presentation and the low index of suspicion among clinicians. Early detection and diagnosis is the fundamental guarantee to improve the prognosis of pediatric CRC patients, and pediatric surgeons enhance the understanding of pediatric CRC and standardize the surgery as much as possible.


  • Open Access

    Bioresponsive hydrogel microfibers for neuroblastoma drug evaluation

    by Taiyu Song, Qiyang Shen, Yi Cheng, Yue Zhi, Guangling Liu, Haozhen Ren, Jinglin Wang

    Chemotherapy remains the primary systemic treatment for patients with neuroblastoma, but the lack of appropriate in vitro tumor microenvironment models has resulted in suboptimal efficacy of chemotherapeutic agents. In this study, we propose innovative bioresponsive hydrogel microfibers that replicate the mechanical properties of extracellular matrix surrounding neuroblastoma cells for assessing tumor drug responses. These microfibers are composed of an alginate/poly (N-Isopropyl acrylamide) shell and a carboxymethyl cellulose core, fabricated by microfluidic technology. Due to the precise manipulation afforded by microfluidics, it is possible to continuously generate fibers that encapsulate cells with uniform size and precise structure. Additionally, the rapid temperature response characteristics enabled the microfibers to mimic the mechanical properties of the extracellular matrix, thereby regulating the cellular pressure environment and rapidly forming highly active three-dimensional tumor spheroids. Ultimately, our findings demonstrate that neuroblastoma spheres within the microfibers display varying sensitivities to different chemotherapy drugs under distinct external pressure conditions. In conclusion, this biomimetic extracellular matrix microfiber offers a dependable foundation for replicating the neuroblastoma microenvironment and facilitating the assessment of clinical drug efficacy.

  • Open Access

    Innovative treatment model for malignant rhabdoid tumor

    by Xinrong Lin, Jian Li, Qiyang Shen, Lulu He, Jianfeng Zhou, Tao Li, Li Zhou

    MRT is a highly malignant tumor that commonly occurs in children. Despite the current multidisciplinary treatment approach combining surgery, chemotherapy, and radiotherapy, the 3-year survival rate for affected children remains significantly low. This article presents three cases where a novel chemotherapy regimen and maintenance therapy were employed in conjunction with surgical and radiation treatments, resulting in favorable therapeutic outcomes. These findings demonstrate the feasibility and potential of the innovative personalized treatment approach utilized. Personalized treatment involves tailoring therapeutic strategies to the specific characteristics and biological behavior of individual patients. This approach holds promise in improving outcomes for children with MRT. Further research and clinical application will contribute to advancing the use of personalized treatment in the management of MRT.

  • Open Access

    Role of Image-defined risk factors in clinical practice of neuroblastoma: A systematic review and meta-analysis

    by Qiyang Shen, Qi Han, Hanjun Yin, Li Lu, Tao Li, Jianfeng Zhou

    Purpose: To assess the role of image-defined risk factors in clinical practice of neuroblastoma. Methods: A systematic search was conducted to identify articles about IDRFs. Combined overall results were calculated using fixed effects models. Results: The literature search identified 11 articles including 1338 patients for analysis. There was no difference in amplification of MYCN and tumor site (abdominal tumor) between no IDRFs and any IDRFs group, but there was a significant increase of event free survival (OR: 2.43[1.69, 3.49]; P < 0.00001) and overall survival (OR: 3.15[1.68, 5.89]; P = 0.0004) in no IDRFs group. The incidence of complications (OR: 0.21[0.15, 0.30]; P< 0.00001) was higher in patients with any IDRFs. Furthermore, no IDRFs are correlated with higher rate of earlier INSS stage. Conclusions: IDRFs could be an important adjuvant image monitoring method in NB treatment. IDRFs are valuable to evaluate surgical indications for pediatric surgeon, regardless of surgical ability.